How AI is shortening drug discovery timelines in China

Artificial intelligence is accelerating early-stage drug discovery in China. Insilico Medicine uses generative AI to shrink the timeline for a preclinical drug candidate to roughly one year. That’s a big drop from the typical four-and-a-half years. Their method merges AI-powered target discovery and molecule design with vital lab tests done in China.

Key takeaways

• Generative AI finds drug targets and drafts potential molecules for researchers to assess.
• Important lab work to confirm biological activity happens mainly at automated facilities in China.
• This AI-human process has cut the candidate nomination timeline to around 13 months, with a record of 9 months.
• CEO Alex Zhavoronkov points to China’s research setup, lower costs, and regulatory system for helping speed up the cycle.
• The firm has created 31 preclinical candidates since 2021, with 13 moving to investigational new drug status.

AI-Driven Acceleration of Early Discovery

Insilico Medicine has cut the time to produce drug candidates to about a year by blending artificial intelligence with lab research. CEO Alex Zhavoronkov says this beats the standard timeline of roughly four-and-a-half years for the same stage.

Compressed Timelines

Their quickest program nominated a candidate in nine months. The usual timeline sits around 13 months. This covers early discovery and candidate selection.

Generative AI’s Role

Insilico applies generative AI to spot biological targets, design possible drug molecules, and decide which compounds should go to the lab. Their process mixes AI designs with expert review and lab tests, which are still needed to confirm biological activity.

The AI-Human Workflow and Validation Process

Insilico Medicine’s workflow blends AI-generated designs with researcher review and lab validation. Generative AI helps find biological targets and draft potential drug molecules. Researchers then examine these AI designs before they proceed to testing.

Lab experiments are still essential to confirm the biological activity of compounds chosen by AI. This validation and scale-up work happens mostly in China. The firm’s Shanghai site uses automation for biological sampling and compound screening.

Accelerated Timelines

The company’s programs usually nominate a preclinical candidate within 12 to 18 months. This follows the synthesis and testing of 60 to 200 molecules. Their fastest program took just nine months. Standard industry approaches often need about four-and-a-half years to reach the same point.

Output and Geographic Division of Labor

Since 2021, Insilico Medicine has produced 31 preclinical candidates. Thirteen of these programs have gained investigational new drug clearances, allowing them to move into human clinical trials.

Global AI and Local Validation

The company splits its work by geography. AI research and model development occur in places like Montreal and Abu Dhabi. However, a large part of the experimental validation and lab scale-up is done in China.

This split uses specific regional benefits. The Shanghai facility shows this, automating sections of biological sampling and compound screening. Scientists there manage the hands-on testing and scale-up that verify AI designs.

Contributing Factors in China’s Ecosystem

CEO Alex Zhavoronkov credits part of the shorter development cycle to China’s research infrastructure, operating costs, and regulatory setting. The firm does its AI research abroad, but much of the lab validation and scale-up occurs in China.

Infrastructure and Cost Advantages

Their Shanghai site has automated parts of biological sampling and compound screening. Shanghai researchers handle the biological testing and scale-up. Zhavoronkov notes that pharma companies with labs in China can cut about two years from the old candidate selection timeline. This efficiency helps the company typically nominate a candidate within 12 to 18 months, a process that usually takes four-and-a-half years.